OCS
Oculis Holding AG
$27.91
-0.18%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
SEC Reports2
Press Releases5
Recent Activity
May 15, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the ves
May 11, 2026
SEC
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company hi
PRESS-RELEASE — Impact 5/10
May 11, 2026
SEC
Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the s
PRESS-RELEASE — Impact 5/10
May 7, 2026
Press
Oculis announced FDA Special Protocol Assessment (SPA) agreement for the PIONEER-1 Phase 3 trial of Privosegtor in optic
Impact 7/10
May 5, 2026
Press
Oculis presented DME AWARE Delphi study results at ARVO 2026, reinforcing unmet need for non-invasive early DME treatmen
Impact 5/10
Price Targets
$49.20
+76.3% upside
Strong Buy
Current $27.91
Low $41.98
Median $48.70
High $64.18
9 analysts
$41.98
$64.18
Analyst Ratings
6Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 12, 2026 | Needham | MAINTAIN | Buy → Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 5, 2026 | Stifel | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 ▲ +7.3% | $-0.45 — $-0.35 | 18% YoY | 7 |
| Next Q | $-0.44 ▲ +4.1% | $-0.53 — $-0.37 | -37% YoY | 7 |
| Current FY | $-1.76 ▼ -0.9% | $-2.00 — $-1.40 | 7% YoY | 8 |
| Next FY | $-1.64 ▲ +2.8% | $-2.91 — $-0.42 | 7% YoY | 8 |
Latest Reports
NEUTRAL
PRESS-RELEASE
5/10
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company hi
May 11, 2026
NEUTRAL
PRESS-RELEASE
5/10
Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the s
May 11, 2026
BULLISH
Press
7/10
Oculis announced FDA Special Protocol Assessment (SPA) agreement for the PIONEER-1 Phase 3 trial of Privosegtor in optic
May 7, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
BULLISH
7/10
Oculis announced FDA Special Protocol Assessment (SPA) agreement for the PIONEER-1 Phase 3 trial of
May 7, 2026
NEUTRAL
5/10
Oculis presented DME AWARE Delphi study results at ARVO 2026, reinforcing unmet need for non-invasiv
May 5, 2026
MIXED
6/10
Oculis announced completion of the final patient visit in its Phase 3 DIAMOND program for OCS-01, a
Apr 20, 2026
BULLISH
8/10
Oculis Holding AG announced positive Phase 2 ACUITY trial results for its investigational neuroprote
Mar 16, 2026
MIXED
7/10
Oculis reported its 2025 financial results and clinical progress, highlighting a strong cash positio
Mar 3, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 15 analysts: 6 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$49.20 mean target
+76.3% upside
Strong Buy (1.30)
$41.98 Low
$64.18 High
| Metric | Value |
|---|---|
| Current Price | $27.91 |
| Target Low | $41.98 |
| Target Mean | $49.20 |
| Target Median | $48.70 |
| Target High | $64.18 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.45 | $-0.35 | 17.8% | +7.3% | 2↑ 0↓ | $0.0B | -39.5% | 7 |
| Next Q 2026-09-30 |
$-0.44 | $-0.53 | $-0.37 | -36.7% | +4.1% | 2↑ 0↓ | $0.0B | -35.0% | 7 |
| Current FY 2026-12-31 |
$-1.76 | $-2.00 | $-1.40 | 6.7% | -0.9% | 1↑ 1↓ | $0.0B | 343.2% | 8 |
| Next FY 2027-12-31 |
$-1.64 | $-2.91 | $-0.42 | 7.1% | +2.8% | 1↑ 0↓ | $0.1B | 910.3% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.403 | |
| 7d ago | $-0.434 | +0.031 |
| 30d ago | $-0.434 | +0.032 |
| 60d ago | $-0.434 | +0.032 |
| 90d ago | $-0.425 | +0.022 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 5, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | JP Morgan | INITIATE | — | Overweight |
| Dec 3, 2025 | LifeSci Capital | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 15, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to
May 14, 2026
earnings
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
<p align="justify">ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today
May 14, 2026
earnings
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
<p align="justify">ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today
May 11, 2026
earnings
Oculis Reports Q1 2026 Financial Results and Provides Company Update
<p align="justify">ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutic
May 11, 2026
earnings
Oculis Reports Q1 2026 Financial Results and Provides Company Update
<p>ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify">Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biophar
May 11, 2026
earnings_calendar
OCS Q1 2026 Earnings Before Market Open — 2026-05-11
May 7, 2026
other
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
<p>ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify">Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global bioph
May 7, 2026
announcement
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
<p align="justify">ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused
May 7, 2026
earnings_calendar
OCS Q1 2026 Earnings Before Market Open — 2026-05-07
May 5, 2026
fda
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
<p align="justify">ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutic
May 5, 2026
routine
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
<p>ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify">Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biophar
May 1, 2026
routine
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
<p align="justify">ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutic
May 1, 2026
routine
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
<p>ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify">Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biophar
Apr 23, 2026
short_interest
FTD: OCS — 55,494 shares ($1.5M) failed to deliver
Settlement: 20260423, Price: $27.85, FTD Value: $1,545,507.9, OCULIS HLDG AG NAMEN AKT (CHE)
Apr 21, 2026
other
Oculis Publishes Invitation to the Annual General Meeting
<p align="justify">ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the i